US FDA Grants Orphan Drug Designation (ODD) for CAM2029 to Treat Polycystic Liver Disease
The company ‘Camurus’ announced, the US FDA has granted the orphan drug designation (ODD) for the investigational medicinal product of the company known as octreotide subcutaneous depot (CAM2029), used for the treatment of the autosomal dominant polycystic liver disease in the people. Dr. Fredrik Tiberg, CEO and head of Research and Development at Camurus said, […]
Continue Reading